Omnes is selling its minority stake in Cogepart to Bpifrance, Amundi Private Equity Funds and Sofipaca
After six years supporting its development, the Omnes Mid Cap Buyout & Growth Capital team is selling its stake in Cogepart to the Bpifrance, Amundi Private Equity Funds (PEF) and Sofipaca consortium. Omnes acquired its stake in Cogepart in 2015 as part of an owner buyout (OBO) transaction structured by the Omnes Croissance 4 fund. This is the fund's third sale.
Founded in 1986, Cogepart is a French leader in last-mile delivery, a specialist in the highly demanding automotive spare parts aftermarket, a preferred partner in the food retail and furniture sectors, and a major e-commerce provider. The group operates in both urban and rural areas, with a headcount of over 1,900 employees.
During its partnership with Omnes, the group tripled in size, mainly through organic growth but also thanks to a selective external growth strategy. Its regional coverage expanded significantly from 45 to 68 cities (including the recent opening of a premises in Belgium).
Jérôme Dor, Chairman and majority shareholder of Cogepart: “Our group tripled its business volume in five years after Omnes came on board. We now plan to continue this growth in France and abroad, beyond our current operations in Belgium, Luxembourg and southern Germany, and to decarbonise 100% of our fleet by 2025. Omnes and its expert teams were a valuable asset from the outset. I had been looking for a genuine partnership and I was fortunate to get it.”
Jess Wizman, Director, Omnes: “We are delighted to have supported Jérôme Dor over the last six years and to have witnessed the hyper growth of the Cogepart group, which has performed well beyond the initial plan. This success is the result of sustained sales momentum steered by Jérôme Dor, and the company’s unique ability to effectively cover the whole of France.”
Benjamin Arm, Managing Partner in charge of Buyout & Growth Capital, Omnes: “Cogepart fits perfectly with the profile of mid-caps we look for: companies with strong growth potential, mastery of primary transactions, value creation driven by organic growth and an active acquisitions policy. This transaction illustrates the relevance of our investment strategy, which we are carrying over in our new Omnes Croissance 5 fund focused on healthcare, technology and B2B services.”
- Omnes: Benjamin Arm, Jess Wizman
- A Plus Finance: Hervé Legoupil
- Bpifrance Investissement: Stanislas Panhard, Romain Verani, Emmanuel Denoulet, Georges Weill, Charlotte Fadlallah
- Amundi PEF: Claire Chabrier, Frédéric Labia, Jean Karbouyan
- Sofipaca: Alexandre Flageul, Jean Philippe Rebuttini
- M&A advisers: Blue Side (Emmanuel Xerri, Alexandre Forget)
- Legal advice: Numa Avocats (François Perruchot-Triboulet, Olivier Decourchelle)
- Vendor financial due diligence: Advance Capital (Thomas Bettan, Gueorgui Gueorguiev)
- Strategic advice: Advancy (Sébastien Revel, Rémi Cornubert)
- Financial due diligence: KPMG (Mohamed Macaigne, Federico Manassero)
- Legal due diligence: LCDM (Pierre-Louis Sevegrand, Jean-François Rage)
- ESG due diligence: KPMG (Nicolas Cottis, Franck Thiam)
- IT due diligence: KPMG (Laurent Gobbi, Mehdi Alaoui Mrani)